Lilly Calls It Quits On Pegilodecakin As Loxo Team Reorganizes Cancer R&D

 
• By Joseph Haas
Pruning of ornamental trees by scissors
Lilly said it has no plans for further trials of pegilodecakin and terminated three earlier-stage cancer candidates

More from Earnings

More from Business